Evidence map›Paper›PMID 42908949›Full record

ArticleFrontiers in immunology2026

A novel double-mAb sandwich ELISA utilizing broad-spectrum neutralizing antibodies as an

Meina Cai, Xi Wu, Leitai Shi, Jincheng Tong, Chenchen He, Jianhui Nie, Yi Yang, Jinkai Ren, Yuhua Li, Qunying Mao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meina Cai *Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Drug Control (NIDC), Beijing, China.
Xi Wu *Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Drug Control (NIDC), Beijing, China.
Leitai Shi *Department of Arboviral Vaccine, National Institutes for Drug Control (NIDC), Beijing, China.
Jincheng TongDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Drug Control (NIDC), Beijing, China.
Chenchen HeShenyang Pharmaceutical University, Shenyang, China.
Jianhui NieDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Drug Control (NIDC), Beijing, China.
Yi YangBiocytogen Pharmaceuticals Co., Ltd., Beijing, China.
Jinkai RenBeijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China.
Yuhua LiDepartment of Arboviral Vaccine, National Institutes for Drug Control (NIDC), Beijing, China.
Qunying MaoDepartment of Arboviral Vaccine, National Institutes for Drug Control (NIDC), Beijing, China.
Youchun WangChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Shouchun CaoDepartment of Arboviral Vaccine, National Institutes for Drug Control (NIDC), Beijing, China.
Weijin HuangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Drug Control (NIDC), Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rabies remains a devastating zoonotic disease, with prevention measures relying heavily on post-exposure prophylaxis (PEP). Evaluating rabies vaccine potency traditionally relies on the Methods: In this study, we characterized three human-mouse chimeric mAbs (05-2F10, 06-2A12, and 07-4D8-1C1) with broad-spectrum neutralizing activity. Leveraging Results: The three chimeric mAbs exhibited exceptional Conclusion: Collectively, these findings provide a robust technical framework for replacing the traditional NIH potency assay with a reliable

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralRabiesRabies VaccinesRabies virusVaccine PotencyAnimalsEnzyme-Linked Immunosorbent AssayHumansMiceNeutralization TestsUnited StatesAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralRabies VaccinesELISAin vitro alternative methodmonoclonal antibodiespseudovirus neutralizationrabies virus

Identifiers

PMID42908949
PMCPMC13683624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.